FAB
NEUTRALFusion Antibodies Announces Posting of Annual Report & Notice of AGM
The biotechnology company has announced the posting of its annual report and notice of the upcoming annual general meeting.
Fusion Antibodies
16.75GBX
-4.29%
Market Cap
19.04M
Volume
800.31k
51% of avg
P/E Ratio
-6.70
EPS (TTM)
-2.5
Beta
0.59
Day Range
16.50p - 17.99p
52 Week Range
3.80p16.75p21.00p
16.75p
Upcoming Events
FAB
NEUTRALFusion Antibodies Provides OptiMAL R&D Update
The biotechnology company reports progress in validating its antibody discovery platform for use by the National Cancer Institute.
FAB
NEUTRALFusion Antibodies to Host Belfast Investor Presentation
The biotechnology company is hosting an in-person investor presentation in Belfast, Northern Ireland on 18 September 2025.
FAB
NEUTRALFusion Antibodies Reports 73% Revenue Growth in FY2025 Results
The biotechnology firm reported a 73% revenue increase and positive gross profit, but continues to face significant operating losses and cash burn. Its diversification strategy shows promise, particularly in diagnostics.
FAB
GOODFusion Antibodies Wins New Humanisation Project Contract with Global Pharmaceutical Company
The biotechnology company has been selected to proceed with a new humanisation project under an existing agreement with a US-based division of a global pharmaceutical firm, highlighting its expertise in delivering therapeutic antibodies.
FAB
GOODFusion Antibodies Secures Additional Contracts with Existing Client
The biotechnology company has secured additional contracts with an existing client, extending the scope of an ongoing project and adding a new engineering project. The contracts are valued at around £460,000, with a minimum of £400,000 expected to be recognized in the current financial year.
FAB
NEUTRALFusion Antibodies Announces Investor Presentation Dates
The biotechnology company announces dates for upcoming investor presentations in London and Belfast.
FAB
NEUTRALFusion Antibodies Secures U.S. Patent for OptiMAL Platform
The biotechnology company has been granted a U.S. patent for its antibody discovery and engineering platform, OptiMAL.
FAB
NEUTRALFusion Antibodies Receives US Patent Notification
The biotechnology company receives notification that a key patent application has been approved by the US Patent Office, a positive step for the business.
FAB
NEUTRALFusion Antibodies Director Increases Stake
The non-executive director of the biotechnology company has increased his stake through the distribution of shares from a venture capital fund.